uniQure N.V.
QURE
Updated: 23/09/2026, 12:59:42
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
No summaries found.
- Share price
- $45.28
- Market cap
- $3.14B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Matthew C. Kapusta
- Employees
- 221
- IPO date
- 05/02/2014
- Beta
- 0.944
- Last dividend
- $0.00
- Day range
- $44.50 – $45.80
- 52-week range
- $8.73 – $71.50
- 1-day performance
- 2.19%
- 1-year performance
- 418.67%
- Current drawdown (1Y)
- -36.67%
- CIK
- 0001590560
- CUSIP
- N/A
- ISIN
- NL0010696654
- Created
- 07/12/2025, 13:54:18
- Last update
- 23/09/2026, 12:59:42
Track uniQure N.V. with an AI analyst
See which prediction-market events move QURE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Analyst Adjusts Price Target for uniQure (NASDAQ:QURE) Amid Mixed Financials and Clinical Progress
Market Data • Market Data • 06/05/2026, 18:26:37
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 05/05/2026, 17:41:26
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
GlobeNewsWire • STOCK • 05/05/2026, 09:05:00
uniQure to Announce First Quarter 2026 Financial Results
GlobeNewsWire • STOCK • 28/04/2026, 09:05:00
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE
GlobeNewsWire • STOCK • 13/04/2026, 17:10:00
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp • STOCK • 13/04/2026, 15:51:00
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
GlobeNewsWire • STOCK • 13/04/2026, 11:00:00
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
PRNewsWire • STOCK • 13/04/2026, 01:54:00
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
PRNewsWire • STOCK • 13/04/2026, 01:53:00
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
PRNewsWire • STOCK • 12/04/2026, 15:31:00
QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Newsfile Corp • STOCK • 12/04/2026, 13:03:00
QURE DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE
Newsfile Corp • STOCK • 11/04/2026, 14:10:00